Kamada Company Profile (NASDAQ:KMDA)

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMDA
  • CUSIP: N/A
  • Web: www.kamada.com
Capitalization:
  • Market Cap: $171.18 million
  • Outstanding Shares: 37,400,000
Average Prices:
  • 50 Day Moving Avg: $4.49
  • 200 Day Moving Avg: $6.19
  • 52 Week Range: $3.75 - $8.61
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.75
  • P/E Growth: 8.70
Sales & Book Value:
  • Annual Revenue: $87.83 million
  • Price / Sales: 2.02
  • Book Value: $1.83 per share
  • Price / Book: 2.60
Profitability:
  • EBIDTA: $1.94 million
  • Net Margins: -2.24%
  • Return on Equity: -2.94%
  • Return on Assets: -2.03%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 2.85%
  • Quick Ratio: 1.95%
Misc:
  • Average Volume: 173,698 shs.
  • Beta: 1.04
  • Short Ratio: 0.08
 

Frequently Asked Questions for Kamada (NASDAQ:KMDA)

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Tuesday, August, 1st. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.12 by $0.01. The firm earned $32.55 million during the quarter, compared to analyst estimates of $33.30 million. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The business's quarterly revenue was up 70.7% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. View Kamada's Earnings History.

When will Kamada make its next earnings announcement?

Kamada is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Kamada.

Where is Kamada's stock going? Where will Kamada's stock price be in 2017?

2 equities research analysts have issued 12-month target prices for Kamada's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Kamada's share price to reach $8.50 in the next twelve months. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:

  • Leon Yehuda Recanati, Chairman of the Board
  • Amir London, Chief Executive Officer
  • Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
  • David Tsur, Deputy Chairman of the Board
  • Ruth Wolfson, Senior Vice President - Scientific Affairs
  • Barak Bashari, Vice President - Operations
  • Shani Dotan, Vice President - Human Resources
  • Yael Brenner, Vice President - Quality
  • Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D
  • Eran Schenker, Vice President - Medical Director

Who owns Kamada stock?

Kamada's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BROSH CAPITAL PARTNERS L.P. (6.20%), Paulson & CO. Inc. (2.17%), Vanguard Group Inc. (1.30%), Migdal Insurance & Financial Holdings Ltd. (1.27%), Nexthera Capital LP (0.83%) and Navellier & Associates Inc (0.14%). View Institutional Ownership Trends for Kamada.

Who sold Kamada stock? Who is selling Kamada stock?

Kamada's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Kamada.

Who bought Kamada stock? Who is buying Kamada stock?

Kamada's stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Paulson & CO. Inc., Navellier & Associates Inc, Vanguard Group Inc. and Edmond DE Rothschild Holding S.A.. View Insider Buying and Selling for Kamada.

How do I buy Kamada stock?

Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of Kamada stock can currently be purchased for approximately $4.75.


MarketBeat Community Rating for Kamada (NASDAQ KMDA)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Kamada (NASDAQ:KMDA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (78.95% upside)

Analysts' Ratings History for Kamada (NASDAQ:KMDA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/2/2017Jefferies Group LLCReiterated RatingBuy$9.00 -> $7.00LowView Rating Details
2/7/2017HC WainwrightSet Price TargetBuy$10.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Kamada (NASDAQ:KMDA)
Earnings by Quarter for Kamada (NASDAQ:KMDA)
Earnings History by Quarter for Kamada (NASDAQ KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017        
8/1/20176/30/2017$0.12$0.13$33.30 million$32.55 millionViewListenView Earnings Details
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kamada (NASDAQ:KMDA)
2017 EPS Consensus Estimate: $0.17
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.00$0.00$0.00
Q2 20171$0.10$0.10$0.10
Q3 20171$0.02$0.02$0.02
Q4 20171$0.05$0.05$0.05
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kamada (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Kamada (NASDAQ:KMDA)
Latest Headlines for Kamada (NASDAQ:KMDA)
Source:
DateHeadline
finance.yahoo.com logoKamada Announces CFO Transition
finance.yahoo.com - September 18 at 7:45 PM
finance.yahoo.com logoETFs with exposure to Kamada Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 3:56 AM
finance.yahoo.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 6:57 AM
americanbankingnews.com logoAnalyzing Syros Pharmaceuticals (SYRS) & Kamada (KMDA)
www.americanbankingnews.com - September 7 at 10:03 AM
feeds.benzinga.com logoKamada to Present Corporate Overview at Two Investor Conferences in September
feeds.benzinga.com - September 7 at 8:20 AM
finance.yahoo.com logoKamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action
finance.yahoo.com - September 6 at 8:42 PM
americanbankingnews.com logoKamada Ltd. (KMDA) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - September 2 at 11:50 PM
finance.yahoo.com logoKamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 31 at 6:44 AM
streetinsider.com logoKamada (KMDA) Says FDA Issued Letter Stating that it Continues to Have Concerns and Questions About Safety and Efficacy of Inhaled AAT
www.streetinsider.com - August 29 at 5:59 AM
americanbankingnews.com logoFY2018 EPS Estimates for Kamada Ltd. Lowered by Jefferies Group (KMDA)
www.americanbankingnews.com - August 28 at 9:04 AM
finance.yahoo.com logoKedrion Biopharma and Kamada Receive FDA Approval of KEDRAB™ for Post-Exposure Prophylaxis Against Rabies Infection
finance.yahoo.com - August 25 at 7:41 AM
americanbankingnews.com logoReviewing Kamada (KMDA) & MediWound (MDWD)
www.americanbankingnews.com - August 21 at 4:26 PM
americanbankingnews.com logo$24.84 Million in Sales Expected for Kamada Ltd. (KMDA) This Quarter
www.americanbankingnews.com - August 18 at 3:32 PM
americanbankingnews.com logoBrokers Issue Forecasts for Kamada Ltd.'s FY2018 Earnings (KMDA)
www.americanbankingnews.com - August 3 at 3:30 PM
americanbankingnews.com logoJefferies Group LLC Reiterates Buy Rating for Kamada Ltd. (NASDAQ:KMDA)
www.americanbankingnews.com - August 2 at 4:38 PM
americanbankingnews.com logoKamada Ltd. to Post Q3 2017 Earnings of $0.02 Per Share, Jefferies Group Forecasts (NASDAQ:KMDA)
www.americanbankingnews.com - August 2 at 7:02 AM
finance.yahoo.com logoKamada Reports Financial Results for Second Quarter and First Six Months of 2017
finance.yahoo.com - August 2 at 2:45 AM
finance.yahoo.com logoKamada posts 2Q profit
finance.yahoo.com - August 2 at 2:44 AM
americanbankingnews.com logoKamada Ltd. (NASDAQ:KMDA) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 1 at 10:47 AM
streetinsider.com logoKamada (KMDA) Prices 3.33M Public Offering at $4.50/Ordinary Share
www.streetinsider.com - July 30 at 5:24 AM
finance.yahoo.com logoKamada Announces Pricing of Public Offering of Ordinary Shares
finance.yahoo.com - July 29 at 1:18 AM
americanbankingnews.com logoZacks: Brokerages Expect Kamada Ltd. (KMDA) to Post $0.12 Earnings Per Share
www.americanbankingnews.com - July 28 at 10:24 PM
finance.yahoo.com logoKamada to Host Second Quarter 2017 Financial Results Conference Call on August 1
finance.yahoo.com - July 28 at 1:34 AM
finance.yahoo.com logoKamada Announces Proposed Public Offering of Ordinary Shares
finance.yahoo.com - July 28 at 1:34 AM
finance.yahoo.com logoKamada Pre-Announces Certain Preliminary Financial Results for Second Quarter and First Six Months of 2017
finance.yahoo.com - July 28 at 1:34 AM
finance.yahoo.com logoKamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
finance.yahoo.com - July 21 at 12:52 AM
finance.yahoo.com logoETFs with exposure to Kamada Ltd. : July 7, 2017
finance.yahoo.com - July 8 at 12:04 PM
americanbankingnews.com logo$32.90 Million in Sales Expected for Kamada Ltd. (NASDAQ:KMDA) This Quarter
www.americanbankingnews.com - July 6 at 10:08 AM
americanbankingnews.com logoZacks: Analysts Anticipate Kamada Ltd. (NASDAQ:KMDA) Will Post Earnings of $0.12 Per Share
www.americanbankingnews.com - July 4 at 6:24 PM
finance.yahoo.com logoKamada Withdraws Inhaled AAT Marketing Application in EU
finance.yahoo.com - June 23 at 6:35 PM
streetinsider.com logoKamada (KMDA) Withdrawal of European MAA for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
www.streetinsider.com - June 23 at 7:34 AM
nasdaq.com logoKamada Ltd. (KMDA) Is Sinking After European Application Withdrawn
www.nasdaq.com - June 23 at 7:34 AM
rttnews.com logoKamada Ltd. (KMDA) Sank To Nearly A 5-Month Low
www.rttnews.com - June 23 at 7:34 AM
finance.yahoo.com logoKamada Announces Withdrawal of European Marketing Authorization Application for Inhaled Alpha-1 Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
finance.yahoo.com - June 22 at 12:44 PM
finance.yahoo.com logoETFs with exposure to Kamada Ltd. : June 16, 2017
finance.yahoo.com - June 16 at 7:04 PM
finance.yahoo.com logoKamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 10:58 AM
streetinsider.com logoKamada (KMDA) Receives Additional Milestone Payment Under GLASSIA Agreement with Shire
www.streetinsider.com - June 13 at 8:36 AM
finance.yahoo.com logoKamada Receives Additional Milestone Payment Under GLASSIA® Exclusive Supply and Distribution Agreement with Shire
finance.yahoo.com - June 12 at 3:21 PM
americanbankingnews.com logo$32.90 Million in Sales Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 10 at 8:22 AM
americanbankingnews.com logo$0.12 Earnings Per Share Expected for Kamada Ltd (KMDA) This Quarter
www.americanbankingnews.com - June 8 at 4:30 PM
finance.yahoo.com logoKamada Provides Update on Clinical Program for Alpha-1 Antitrypsin IV for Treatment of Graft-Versus-Host Disease
finance.yahoo.com - June 7 at 9:39 AM
finance.yahoo.com logoKamada Announces Appointment of Michal Stein, M.D., as Vice President and Medical Director
finance.yahoo.com - June 5 at 9:58 AM
finance.yahoo.com logoKamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
finance.yahoo.com - May 24 at 11:14 AM
americanbankingnews.com logoKamada Ltd (KMDA) to Post Q2 2017 Earnings of $0.10 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 19 at 7:16 AM
americanbankingnews.com logoShort Interest in Kamada Ltd (KMDA) Decreases By 9.0%
www.americanbankingnews.com - May 18 at 4:22 PM
americanbankingnews.com logoKamada Ltd (KMDA) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 18 at 12:30 PM
americanbankingnews.com logoFY2017 EPS Estimates for Kamada Ltd Reduced by Jefferies Group (KMDA)
www.americanbankingnews.com - May 18 at 10:38 AM
finance.yahoo.com logoKamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss
finance.yahoo.com - May 17 at 6:10 PM
americanbankingnews.com logoKamada Ltd (KMDA) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - May 17 at 11:34 AM
americanbankingnews.com logoKamada Ltd (KMDA) Issues Earnings Results
www.americanbankingnews.com - May 17 at 10:03 AM

Social

Chart

Kamada (KMDA) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff